	US 12,071,468 B2
	Purification of Factor VIII subspecies
Meinhard Hasslacher, Vienna (AT); Martin Feichtinger, Vienna (AT); Philipp M. Bärnthaler, Vienna (AT); Christa Mayer, Wolfsthal (AT); Birgit Reipert, Deutsch-Wagram (AT); Mantas Malisauskas, Vienna (AT); and Julia Anzengruber, Vienna (AT)
Assigned to TAKEDA PHARMACEUTICAL COMPANY LIMITED, Osaka (JP)
Filed by TAKEDA PHARMACEUTICAL COMPANY LIMITED, Osaka (JP)
Filed on Mar. 7, 2022, as Appl. No. 17/688,588.
Application 17/688,588 is a division of application No. 16/015,452, filed on Jun. 22, 2018, granted, now 11,299,533.
Claims priority of application No. 17177749 (EP), filed on Jun. 23, 2017.
Prior Publication US 2022/0275058 A1, Sep. 1, 2022
Int. Cl. C07K 14/755 (2006.01); A61K 38/00 (2006.01); B01D 15/32 (2006.01); B01D 15/34 (2006.01); B01D 15/36 (2006.01); C07K 1/16 (2006.01); C07K 1/18 (2006.01); C07K 1/36 (2006.01)

CPC C07K 14/755 (2013.01) [B01D 15/327 (2013.01); B01D 15/34 (2013.01); B01D 15/363 (2013.01); C07K 1/16 (2013.01); C07K 1/18 (2013.01); C07K 1/36 (2013.01); A61K 38/00 (2013.01)]

16 Claims

1. A method for treating a bleeding disorder in a patient, the method comprising the step of administering to the patient in need of such treatment a therapeutically effective amount of a composition comprising:

a Factor VIII (FVIII) subspecies produced by anion exchange chromatography of a composition comprising FVIII, wherein said FVIII subspecies is a FVIII heavy chain that is associated with a FVIII light chain, and wherein the weight ratio of said FVIII subspecies in the composition is increased as compared to all other FVIII subspecies comprising a FVIII heavy chain that is associated with a FVIII light chain.